Drugs / CT053PTSA
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03125876 | Nov 2017 → Aug 2019 | acute myeloid leukemia | Sunshine Lake Pharma Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04577703 | Feb 2014 → Dec 2015 | neoplasm | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04601610 | Jun 2021 → May 2022 | hepatocellular carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT03876925 | Jun 2018 → Mar 2020 | renal cell carcinoma | Sunshine Lake Pharma Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03758287 | Nov 2016 → Sep 2021 | non-small cell lung carcinoma | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04992858 | Nov 2022 → Sep 2024 | non-small cell lung carcinoma | Sunshine Lake Pharma Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT053PTSA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03125876 ↗ |
| Known as | Ningetinib Tosylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04601610 ↗ |
| Action | Inhibit | “Ningetinib Tosylate（multi-target TKI）” NCT04601610 ↗ |
| Modality | Other / unclassified | “Ningetinib Tosylate（multi-target TKI）” NCT04601610 ↗ |
| Route | Oral | “receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days” NCT03125876 ↗ |